Iniparib (previously BSI 201) (4-iodo-3-nitrobenzamide) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification, but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer, but was discontinued after disappointing Phase III clinical trials.

CAS：160003-66-7
中文别名：3-硝基-4-碘苯甲酰胺;
英文别名：Iniparib (BSI-201);4-iodo-3-nitrobenzamide;
分子式：C7H5IN2O3
分子量：292.031
精确质量：291.934
Psa：88.91
Logp：2.5218

MDL号：MFCD11110639

密度：2.056g/cm3
沸点：344.754ºC at 760 mmHg
闪点：162.302ºC
折射率：1.696
蒸汽压：0mmHg at 25°C

海关编码：2924299090
危险性防范说明：P305 + P351 + P338
信号词：Warning
危险性描述：H302; H319
危险标志：GHS07